IL315551A - Formulations containing melphalan flupenamide and cyclodextrin - Google Patents

Formulations containing melphalan flupenamide and cyclodextrin

Info

Publication number
IL315551A
IL315551A IL315551A IL31555124A IL315551A IL 315551 A IL315551 A IL 315551A IL 315551 A IL315551 A IL 315551A IL 31555124 A IL31555124 A IL 31555124A IL 315551 A IL315551 A IL 315551A
Authority
IL
Israel
Prior art keywords
cyclodextrin
formulations
melphalan flufenamide
flufenamide
melphalan
Prior art date
Application number
IL315551A
Other languages
English (en)
Hebrew (he)
Original Assignee
Oncopeptides Innovation Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncopeptides Innovation Ab filed Critical Oncopeptides Innovation Ab
Publication of IL315551A publication Critical patent/IL315551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315551A 2022-03-24 2023-03-24 Formulations containing melphalan flupenamide and cyclodextrin IL315551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (1)

Publication Number Publication Date
IL315551A true IL315551A (en) 2024-11-01

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315551A IL315551A (en) 2022-03-24 2023-03-24 Formulations containing melphalan flupenamide and cyclodextrin

Country Status (11)

Country Link
US (1) US20250205155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499049A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510725A (cg-RX-API-DMAC7.html)
KR (1) KR20240161664A (cg-RX-API-DMAC7.html)
CN (1) CN119053323A (cg-RX-API-DMAC7.html)
AU (1) AU2023241241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202204171D0 (cg-RX-API-DMAC7.html)
IL (1) IL315551A (cg-RX-API-DMAC7.html)
MX (1) MX2024011654A (cg-RX-API-DMAC7.html)
WO (1) WO2023180565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
WO2023180565A1 (en) 2023-09-28
KR20240161664A (ko) 2024-11-12
AU2023241241A1 (en) 2024-10-31
CA3245985A1 (en) 2023-09-28
JP2025510725A (ja) 2025-04-15
CN119053323A (zh) 2024-11-29
GB202204171D0 (en) 2022-05-11
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26
MX2024011654A (es) 2025-01-09

Similar Documents

Publication Publication Date Title
IL295102B2 (en) Formulations and their uses
IL286847B2 (en) HSP90-binding couplers and their formulations
IL309884A (en) Immunoconjugates and methods
GB202217964D0 (en) Pharmaceutical and cosmetic compositions comprising secretomes
IL277791A (en) HSP90 targeting conjugates and their formulations
GB202002900D0 (en) Audio repersentation and associated rendering
IL299806A (en) Preparations and compositions comprising polymer combination preparations
EP4132949A4 (en) RECONSTITUTED RBM FROM SARS-COV2 CORONAVIRUS AND USES THEREOF
IL299254A (en) Tubulysins and protein-tubulysin conjugates
IL325624A (en) Clasps and their uses
EP3980008A4 (en) Modified release formulations and uses thereof
IL299101A (en) Formulations of non-porcine origin and methods for their preparation
ZA202408364B (en) Liquid-dispersible halopyruvate formulations and associated methods
PL3757992T3 (pl) Reprezentacja i renderowanie dźwięku przestrzennego
EP4164619A4 (en) TREATMENT METHODS AND FORMULATIONS
IL318702A (en) Compositions containing G-CSF and their uses
GB202010987D0 (en) Oral care compositions and methods
EP4093278A4 (en) AESTHETICS-ENHANCING FORMULATIONS AND METHODS THEREFOR
HK40092508A (en) Non-porcine formulations and methods thereof
EP3989941A4 (en) SSTR-TARGETING CONJUGATES AND RELATED FORMULATIONS
HK40070046A (en) Hsp90-binding conjugates and formulations thereof
HK40084380A (zh) 制剂及其用途
AU2024377064A1 (en) Cnp variants, conjugates and formulations thereof
CA3311033A1 (en) Cnp variants, conjugates and formulations thereof
HK40105762A (zh) 含阿紮胞苷的新制剂